Abstract
The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF <50% (12%). Based on the intent to treat analysis, overall response rate was 72%, including 28 patients in complete remission (complete remission rate, 56%), and 8 in partial remission (16%). At the end of treatment, grades 3 to 4 cardiac events were observed in 6 patients. No significant modifications from baseline values of LVEF were observed during treatment and follow-up. Nonpegylated liposomal doxorubicin instead of doxorubicin in the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)...Continue Reading
References
Mar 1, 1986·Cancer·R Perez-SolerF Cabanillas
Jul 1, 1971·Circulation·B Lown, M Wolf
Jun 29, 1995·The New England Journal of Medicine·S E LipshultzS D Colan
Dec 30, 1999·The New England Journal of Medicine·L F HutchinsK S Albain
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G BatistL W Lee
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Feb 4, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LimatJ Y Cahn
Mar 14, 2003·Anti-cancer Drugs·Christine E SwensonPhilip Chaikin
Oct 25, 2003·Blood·Marc AndréUNKNOWN Groupe D'Etude Des Lymphomes De L'Adulte
Feb 19, 2005·Seminars in Oncology·Theresa M Allen, Francis J Martin
Feb 19, 2005·Seminars in Oncology·Michael S EwerAlberto A Gabizon
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Oct 31, 2006·Leukemia & Lymphoma·F ZajaR Fanin
Jun 22, 2007·Blood·Andrea GallaminiCorrado Tarella
Jul 27, 2007·Hematological Oncology·Luigi RigacciAlberto Bosi
Oct 3, 2007·Hematology/oncology Clinics of North America·Bruce D Cheson
Jun 24, 2008·Leukemia & Lymphoma·Giuseppe VisaniAlessandro Isidori
Nov 17, 2009·Medicina clínica·Miriam MorenoJosep-María Ribera
Dec 17, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LuminariM Federico
Aug 17, 2010·Leukemia Research·Eva GimenoAntonio Salar
Feb 9, 2011·Blood·Elias CampoElaine S Jaffe
May 27, 2011·Leukemia & Lymphoma·Matteo Dell'OlioCascavilla Nicola
Nov 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul A FieldsDavid Cunnningham
Jun 16, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·M MianM Fiegl
Sep 24, 2015·Leukemia & Lymphoma·Armin RashidiNancy L Bartlett
Mar 19, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michael A FridrikRichard Greil
Jul 8, 2016·Blood·Chiara ElenaMario Cazzola
Citations
Jun 30, 2019·Current Hematologic Malignancy Reports·Murali KesavanGraham P Collins
Jul 25, 2019·Current Opinion in Oncology·Pierre-Louis Soubeyran, Raul Cordoba
Nov 14, 2019·British Journal of Haematology·Ingrid GlimeliusCaroline E Weibull
Jul 10, 2019·Leukemia & Lymphoma·Flavia SalviFrancesco Merli
Apr 28, 2019·Investigational New Drugs·M Christina CoxGerardo Musuraca
Nov 1, 2017·Annals of Hematology·Ting ZhouYongsheng Jiang
May 27, 2020·Annals of Hematology·T SystchenkoP Ingrand
Aug 23, 2020·Current Oncology Reports·Pamela Allen
Feb 8, 2019·Future Oncology·Pieternella J LugtenburgStefano Luminari
Mar 11, 2021·Therapeutics and Clinical Risk Management·Barbara Jezeršek NovakovićAleksander Novaković
Mar 23, 2021·Therapeutic Advances in Hematology·Katrin Schmittlutz, Reinhard Marks
May 28, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ashley E RoskoHeidi D Klepin
Jun 5, 2021·Critical Reviews in Oncology/hematology·Carlo ViscoMauro Krampera
Mar 14, 2021·British Journal of Haematology·Raul CordobaToby A Eyre
Sep 9, 2021·European Journal of Haematology·Marguerite BriandLaurent Balardy